The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.

The Trump administration canceled a Biden-era plan on Friday that would have made Ozempic and other weight-loss drugs ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

It’s why Webb, of Rochester, is fighting for the passage of Indiana Senate Bill 140. The bill, which passed the Indiana ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

A rapidly escalating trade war has socked stocks as investors weigh the fallout from President Trump’s tariff barrage.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...